GSK press releases
Follow
Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease
If approved, GSK’s RSV vaccine would be the first available in Japan to help protect this group
